Sincalide

Cholecystokinin Analog — VARIOUS

Key facts

Sincalide is an ofp drug in the Cholecystokinin Analog class catalogued in DrugCentral. It was first approved by the FDA in 1976. DrugCentral lists 7 molecular targets, including Cckar, CCKBR and CCKAR. Recorded indications include Diagnostic aid and Diagnostic Test for Pancreas Function.

• Approval status: ofp (first approved 1976 by the FDA).
• Drug class: Cholecystokinin Analog.
• Molecular targets: Cckar, CCKBR, CCKAR and CCKAR (7 listed in DrugCentral).
• Indications: Diagnostic aid and Diagnostic Test for Pancreas Function.
• ATC code: V04CC03 (Tests for bile duct patency).
• Molecular formula: C49H62N10O16S3; molecular weight 1143.27 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Diagnostic aid
• Diagnostic Test for Pancreas Function

Contraindications (3)

• Gallstone Complications
• Gastrointestinal obstruction
• Pregnancy, function

Mechanism & targets

• Established pharmacologic class: Cholecystokinin Analog

Molecular targets (7)

Target	Gene	Action	Activity
Cholecystokinin receptor type A	Cckar	unknown	Ki 10.05
Gastrin/cholecystokinin type B receptor	CCKBR	unknown	Ki 9.55
Cholecystokinin receptor type A	CCKAR	unknown	Ki 9.55
Cholecystokinin receptor type A	CCKAR	unknown	Ki 9.55
Gastrin/cholecystokinin type B receptor	Cckbr	unknown	IC50 9.52
Cholecystokinin receptor	Cckar|Cckbr	unknown	Ki 9.52
Gastrin/cholecystokinin type B receptor	Cckbr	unknown	Ki 9.39

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1976-07-21	FDA	—	BRACCO

ATC classification

ATC code	Therapeutic hierarchy
V04CC03	VARIOUS › DIAGNOSTIC AGENTS › OTHER DIAGNOSTIC AGENTS › Tests for bile duct patency

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Multiple use of single-use product	220.6
Therapeutic product effect decreased	162.5

Chemical structure

• Molecular formula: C₄₉H₆₂N₁₀O₁₆S₃
• Molecular weight: 1143.27 g/mol
• CAS number: 25126-32-3
• InChIKey: IZTQOLKUZKXIRV-YRVFCXMDSA-N
• PubChem CID: 9833444

CSCC[C@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Sincalide used for?

DrugCentral lists the following indications for Sincalide: Diagnostic aid and Diagnostic Test for Pancreas Function.

How does Sincalide work?

Its molecular targets in DrugCentral include Cckar, CCKBR, CCKAR and CCKAR.

When was Sincalide first approved?

Sincalide was first approved by the FDA in 1976.

What drug class does Sincalide belong to?

Sincalide is in the Cholecystokinin Analog class.

What is the chemical formula of Sincalide?

Sincalide has the molecular formula C49H62N10O16S3 and a molecular weight of 1143.27 g/mol.

Sources

• DrugCentral drug card 4627 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1121 — compound record and bioactivity
• PubChem CID 9833444 — chemical identifiers
• DrugBank DB09142 — drug record
• FDA UNII M03GIQ7Z6P — substance identity
• DailyMed: FDA labels for Sincalide — current prescribing information (label search)
• UniProt P32239 (CCKBR) — target protein
• UniProt P32238 (CCKAR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.